Acurx Pharmaceuticals, Inc. — fact timeline

Acurx Pharmaceuticals, Inc. entered into Securities Purchase Agreement with the investors named therein (the "Investors") valued at aggregate gross proceeds of approximately $2.5 million (effective 2026-04-15).

“On April 15, 2026, Acurx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the investors named therein (the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the “Registered Offering”) (i) 816,068 shares (the “Shares”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”) at a purchase price of $3.03 per share and (ii) pre-funded common stock purchase warrants (the “Pre-Funded Warrants”) to purchase up to 9,017 shares of Common Stock (the “Pre-Funded Warrant Shares”) at a purchase price of $3.029 per share for aggregate gross proceeds of approximately $2.5 million”

Acurx Pharmaceuticals, Inc.: Amendment to Certificate of Incorporation to increase authorized shares of common stock from 200,000,000 to 250,000,000 (effective 2025-09-22).

“the Company’s stockholders approved an amendment (the “Amendment”) to the Company’s Certificate of Incorporation, as amended, to increase the total number of authorized shares of the Company’s common stock from 200,000,000 to 250,000,000. On September 22, 2025, the Company filed the Amendment with the Secretary of State of the State of Delaware with immediate effect.”

Acurx Pharmaceuticals, Inc.: Filing of certificate of amendment to effect a 1-for-20 reverse stock split of common stock, effective August 4, 2025 at 4:01 p.m. Eastern Time (effective 2025-08-04).

“On July 31, 2025, Acurx Pharmaceuticals, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an amendment (the “Certificate of Amendment”) to its certificate of incorporation to effect a reverse stock split of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a ratio of 1-for-20 (the “Reverse Stock Split”).”

Acurx Pharmaceuticals, Inc. reported the first quarter ended March 31, 2024 results: net income $4.4 million or $0.28 per diluted share, EPS $0.28 per diluted share.

“The Company reported a net loss of $4.4 million or $0.28 per diluted share for the three months ended March 31, 2024”

Acurx Pharmaceuticals, Inc. reported the year ended December 31, 2023 results: net income $14.6.

“oss of $3.3 million or $0.28 per diluted share for the three months ended December 31, 2022, and a net loss of $14.6”

Acurx Pharmaceuticals, Inc. reported the three months ended December 31, 2023 results: net income $5.1 million, EPS $0.37 per diluted share.

“The Company reported a net loss of $5.1 million or $0.37 per diluted share for the three months ended December 31, 2023 compared to a net loss of $3.3 million or $0.28 per diluted share for the three months ended December 31, 2022”